Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.68B | 1.73B | 1.97B | 2.23B | 2.70B | 2.58B | Gross Profit |
1.13B | 1.18B | 1.36B | 1.59B | 2.02B | 1.92B | EBIT |
-20.96M | -151.59M | 48.27M | 110.85M | 233.99M | 257.56M | EBITDA |
46.40M | -78.83M | 138.98M | 231.85M | 368.48M | 331.56M | Net Income Common Stockholders |
-38.55M | -146.59M | 8.60M | 104.78M | 147.27M | 191.35M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
203.77M | 197.99M | 267.82M | 278.51M | 354.81M | 423.90M | Total Assets |
1.39B | 1.47B | 1.81B | 1.82B | 1.91B | 1.96B | Total Debt |
300.71M | 478.23M | 607.33M | 479.01M | 465.04M | 500.38M | Net Debt |
96.94M | 291.34M | 351.27M | 214.28M | 125.45M | 97.69M | Total Liabilities |
637.44M | 817.46M | 984.50M | 923.67M | 993.71M | 1.06B | Stockholders Equity |
753.97M | 651.46M | 821.97M | 897.30M | 912.77M | 894.27M |
Cash Flow | Free Cash Flow | ||||
65.93M | 70.16M | 60.15M | 49.01M | 72.97M | 315.32M | Operating Cash Flow |
108.81M | 111.74M | 118.64M | 108.06M | 141.58M | 379.14M | Investing Cash Flow |
152.84M | -37.96M | -134.50M | -67.08M | -88.73M | -79.43M | Financing Cash Flow |
-267.52M | -133.18M | 10.73M | -99.50M | -104.70M | -245.17M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $12.25B | 78.03 | 36.79% | ― | 85.99% | ― | |
77 Outperform | $13.52B | 41.60 | 17.92% | 0.86% | 8.96% | -22.99% | |
64 Neutral | $633.22M | 5.17 | 7.45% | ― | -4.93% | -23.61% | |
62 Neutral | $6.94B | 11.29 | 2.95% | 3.87% | 2.70% | -24.49% | |
60 Neutral | $4.34B | 40.12 | -10.58% | ― | -1.68% | -302.11% | |
56 Neutral | $207.92M | ― | -70.44% | ― | -17.97% | 49.13% | |
54 Neutral | $389.37M | ― | -4.93% | 3.04% | -11.85% | -1080.00% |
On May 29, 2025, Nu Skin Enterprises held its Annual Meeting of Stockholders, where the stockholders approved the Amended and Restated 2024 Omnibus Incentive Plan. This plan increases the share authorization by 790,000 shares, clarifies the vesting of performance cash awards, and extends the termination date to May 29, 2035. Additionally, the meeting saw the election of nine directors, advisory approval of executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025. These decisions are expected to impact Nu Skin’s operational strategies and governance structure positively.
The most recent analyst rating on (NUS) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Nu Skin stock, see the NUS Stock Forecast page.